What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 5, 2014, Pages 967-970

  Oh, Man S ^a   Uribarri, Jaime ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN GUM; PHOSPHATE; POLYMER; SEVELAMER; UNCLASSIFIED DRUG; CHEWING GUM;

BINDING KINETICS; CHEWING GUM; DISEASE COURSE; DRUG SALIVA LEVEL; HAWTHORNE EFFECT; HYPERPHOSPHATEMIA; NOTE; TREATMENT OUTCOME; TREATMENT RESPONSE; FEMALE; HUMAN; MALE; METABOLISM; RENAL REPLACEMENT THERAPY; SALIVA;

CHEWING GUM; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; PHOSPHATES; RENAL DIALYSIS; SALIVA;

EID: 84904043504     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09230913     Document Type: Note

References (15)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218, 2004.
2. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519–530, 2008.
3. Walsh M, Manns BJ, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B: The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. Hemodial Int 14: 174–181, 2010.
4. Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G: Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 20: 639–644, 2009.
5. Sonne P: Nestle´ Buys ‘Medical Food’ Start-Up. Available at: http://online.wsj.com/article/SB100014240527487-04124504576118273251942458.html. Accessed June 1, 2013.
6. Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, Pergola P, Smits G, Comelli MC: Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract 123: 93–101, 2013.
7. Kjellstrand CM, Ing TS, Kjellstrand PT, Odar-Cederlof I, Lagg CR: Phosphorus dynamics during hemodialysis. Hemodial Int 15: 226–233, 2011.
8. Mazzeo JR, Peters RM, Hanus MR, Chen X, Norton KA: A phosphate binding assay for sevelamer hydrochloride by ion chro-matography. J Pharm Biomed Anal 19: 911–915, 1999.
9. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407–1415, 2012.
10. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286–291, 2010.
11. Filion D, Lavertu M, Buschmann MD: Ionization and solubility of chitosan solutions related to thermosensitive chitosan/glycerol-phosphate systems. Biomacromolecules 8: 3224–3234, 2007.
12. Pillai CKS, Paul W, Sharma CP: Chitin and chitosan polymers: Chemistry, solubility and fiber formation. Prog Polym Sci 34: 641–678, 2009.
13. Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR: Bile acid binding to sevelamer HCl. Kidney Int 62: 611–619, 2002.
14. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P: The Hawthorne Effect: A randomised, controlled trial. BMC Med Res Methodol 7: 30, 2007.
15. Phosphate-Binding Chitosan and Uses Thereof. US Patent 7943597. Available at: http://patft.uspto.gov/netahtml/PTO/search-bool.html. Accessed June 1, 2013.